Publications by authors named "Tim M Illidge"

Claim this Profile
A
An International Lymphoma Radiation Oncology Group Study of Radiation Therapy for Bilateral Indolent Orbital Adnexal Lymphomas.
Krystel Tran, Dongryul Oh, Richard Tsang, Chang-Ok Suh, Hong In Yoon, Tim M Illidge

Int J Radiat Oncol Biol Phys· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
Debayan Mukherjee, Erminia Romano, Richard Walshaw, Leo A H Zeef, Antonia Banyard, Tim M Illidge

Oncoimmunology· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress and pitfalls with the use of image-guided personalised approaches in lymphoma.
Tim M Illidge, Elizabeth H Phillips

Br J Radiol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations.
Madyson Colton, Eleanor J Cheadle, Jamie Honeychurch, Tim M Illidge

Radiat Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?
Elizabeth H Phillips, Tim M Illidge

Br J Haematol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines.
Andrew Wirth, N George Mikhaeel, Berthe M P Aleman, Chelsea C Pinnix, Louis S Constine, Tim M Illidge

Int J Radiat Oncol Biol Phys· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma.
Mahsa Eskian, MirHojjat Khorasanizadeh, Pier Luigi Zinzani, Tim M Illidge, Nima Rezaei

Int Rev Immunol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma.
Tim M Illidge, Elizabeth H Phillips, Nicholas Counsell, Ruth Pettengell, Peter W M Johnson

Blood Adv· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How do we move towards a personalised approach in the treatment of Early Hodgkin lymphoma?
Maja V Maraldo, Tim M Illidge

Br J Haematol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment.
Emma J Searle, Brian A Telfer, Debayan Mukherjee, Duncan M Forster, Barry R Davies, Tim M Illidge

EMBO Mol Med· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?
Richard C Walshaw, Jamie Honeychurch, Tim M Illidge

Br J Radiol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
Tim M Illidge, Hayley S McKenzie, Sam Mayes, Andrew Bates, Andrew J Davies

Br J Haematol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.
Simon J Dovedi, Amy L Adlard, Grazyna Lipowska-Bhalla, Conor McKenna, Sherrie Jones, Tim M Illidge

Cancer Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus guidelines for the detection of immunogenic cell death.
Oliver Kepp, Laura Senovilla, Ilio Vitale, Erika Vacchelli, Sandy Adjemian, Tim M Illidge

Oncoimmunology· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor.
Tim M Illidge, Eleanor J Cheadle, Jamie Honeychurch

Leuk Lymphoma· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.
Tim M Illidge, Sam Mayes, Ruth Pettengell, Andrew T Bates, Mike Bayne

J Clin Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab.
Eleanor J Cheadle, Lauren Sidon, Simon J Dovedi, Monique H M Melis, Waleed Alduaij, Tim M Illidge

Br J Haematol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obinutuzumab (GA101)--a different anti-CD20 antibody with great expectations.
Tim M Illidge

Expert Opin Biol Ther· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway.
Jamie Honeychurch, Waleed Alduaij, Mahsa Azizyan, Eleanor J Cheadle, Helene Pelicano, Tim M Illidge

Blood· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New antibody drug treatments for lymphoma.
Sam Mayes, Nick Brown, Tim M Illidge

Expert Opin Biol Ther· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.
Waleed Alduaij, Andrei Ivanov, Jamie Honeychurch, Eleanor J Cheadle, Sandeep Potluri, Tim M Illidge

Blood· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The future of anti-CD20 monoclonal antibodies: are we making progress?
Waleed Alduaij, Tim M Illidge

Blood· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date?
Tim Martin Illidge

J Clin Oncol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma.
Waleed Alduaij, Tim M Illidge

Curr Oncol Rep· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.
Andrei Ivanov, Stephen A Beers, Claire A Walshe, Jamie Honeychurch, Waleed Alduaij, Tim M Illidge

J Clin Invest· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis